Priming Immunotherapy in Advanced Disease With Radiation
Status:
Recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck
squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint
inhibitor (such as Nivolumab, Atezolizumab or Pembrolizumab) for disease treatment as per FDA
approved guidelines. In these patients we will deliver a short-course radiation to a single
systemic (non-CNS) site within 14 days of receiving the first dose of immune checkpoint
inhibitors. This sequence allows radiation to release tumor antigens from immune inaccessible
areas such as necrotic tumor or low perfusion to provide a robust anti-tumor immune response
with immune checkpoint inhibitors.
The primary objective is to assess six-month progression free survival (PFS) compared to
historical control.